Review Article

103

Pharmaceutical Sciences and Research (PSR), 8(3), 2021, 103 - 120

The Effect of Heparinoid as Systemic Prophylactic Anticoagulants
on COVID-19 Patient Mortality and Its Safety Profiles: A Systematic
Review and Meta-Analysis
Ariska Deffy Anggarany1, Rani Sauriasari1*, Muhammad Alkaff2, Famila Takhwifa1,
Hayatun Nufus2, Diana Paramita2
1
2

Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia
Department of Internal Medicine, Persahabatan Central General Hospital, Jakarta, Indonesia
ABSTRACT

ARTICLE HISTORY
Received: October 2021
Revised: November 2021
Accepted : December 2021

Coagulopathy is one of the complications of COVID-19 and is associated with a higher risk of
mortality. However, evidence regarding the effectiveness and safety of anticoagulant therapy in
various doses among COVID-19 patients is limited. This systematic review and meta-analysis
aims to review and explore the effect of using heparinoids as a systemic anticoagulant at
prophylactic doses on mortality in COVID-19 patients. Systematic searches were conducted of
various databases (Pubmed, ScienceDirect, SpringerLink, Scopus, and ProQuest) covering the
period 2019-2021. We assessed the quality of the articles using the STROBE checklist. Studies
with a high risk of bias were excluded before pooled effect size was synthesized with 95%
confidence intervals (CI) using random-effects models. From the 12 identified studies (N=8,968),
six observational studies (N=7,176) were involved in the meta-analysis. The studies reviewed in
the paper used a retrospective cohort design in various settings. The pooled effect size of mortality
comparing prophylactic anticoagulant and no anticoagulant in three studies showed that there was
an association between using prophylactic anticoagulant and a lower risk of in-hospital mortality
(pooled OR= 0.47; 95% CI 0.19-0.76). A prophylactic dose of heparinoid anticoagulant was also
associated with lower mortality (pooled OR= 0.51; 95% CI 0.21-0.82) and with lower bleeding
events compared to intermediate-to-therapeutic dose anticoagulants. Administration of heparinoid
anticoagulants at prophylactic doses was associated with reduced mortality risk in hospitalized
COVID-19 patients. Due to the increased risk of bleeding with therapeutic doses, the use of
prophylaxis anticoagulant is suggested in COVID-19 patients who are not critically ill.
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INTRODUCTION
In late December 2019, the highly infectious coronavirus
rapidly spread worldwide and caused coronavirus
disease 2019 (COVID-19). Severe respiratory illness
can be induced by the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) (Zhu et al., 2020).
Several studies have shown that SARS-CoV-2 virus
infection is linked to substantial coagulation system
activity, leading to prothrombotic conditions (AbouIsmail et al. 2020; Bikdeli et al., 2020). Coagulopathy
is one of the COVID-19 complications that can cause
mortality (chiefly in patients with severe COVID-19)
(Zhou et al., 2020). It can lead to vascular complications,
especially venous thromboembolism (VTE), also known
as Deep Vein Thromboembolism (DVT) or Pulmonary
Embolism (PE), which have been widely reported to
have significant implications for the clinical outcome
of COVID-19 patients (Klok et al., 2020; Langer
et al., 2020). A cohort study of 191 patients with
COVID-19 reported that 50% of in-hospital deaths

were in individuals who had coagulopathy (Zhou et al.,
2020). The occurrence of coagulopathy as part of the
systemic inflammatory response syndrome is a frequent
feature of severe COVID-19. Almost 20% – 50% of
COVID-19 hospitalized patients had hematologic
abnormalities in coagulation testing, and up to 71.4%
of COVID-19 deaths are caused by Disseminated
Intravascular Coagulopathy (DIC) (Gómez-Mesa et al,
2021). Prophylactic anticoagulant has been linked to a
reduction in the incidence of thrombosis and death in
patients; as a result, it can help prevent and decrease
COVID-19 mortality (Langer et al., 2020). The use of
Low Molecular Weight Heparin (LMWH) as an initial
anticoagulant in COVID-19 patients has been shown to
lower mortality by 48% after 7 days, and 37% after 28
days (Gómez-Mesa et al., 2021). Therefore, managing
coagulopathy, including thromboembolic prophylaxis
and anticoagulant treatment, is essential for optimizing
specific therapy and reducing mortality. Guidelines from
the International Society of Thrombosis Haemostasis
(ISTH) recommend prophylactic systemic anticoagulant
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using LMWH among all hospitalized patients,
regardless of their coagulopathy status (Thachil et al.,
2020). Heparin is recommended because, apart from
being an anticoagulant, it theoretically acts as an antiinflammatory and antiviral (Hippensteel et al., 2020).
Systemic heparinoid anticoagulants, both Unfractionated
Heparin (UFH) and LMWH, have been reported to
be more beneficial than oral anticoagulants for use in
COVID-19 hospitalized patients. There is a higher risk
of interaction between antivirals or other drugs with oral
anticoagulants, rather than with systemic anticoagulants
(Weeks, Connors, & Connell, 2021).
Several clinical studies regarding the assessment of the
effect of prophylactic anticoagulants are ongoing. Tang
et al. (2020) reported that prophylactic anticoagulants
had a greater survival rate than no anticoagulant in a
severely ill patient COVID-19, elevated D-dimer values,
and coagulopathy (Tang et al., 2020). Dosage increases
may be necessary because the incidence of thrombosis
is still high, despite prophylactic anticoagulants
(Patel et al., 2020). However, in-hospital mortality in
prophylactic and therapeutic doses has been reported
to be not significantly different, while therapeutic
doses have increased bleeding complications more
than prophylactic doses (Klok et al., 2020; Nadkarni
et al., 2020). Therefore, it can be seen that the role of
anticoagulants at higher doses remains controversial
today.
For this reason, we accomplish a systematic review
of several previous studies with more recent time
on the effect of the prophylactic use of systemic
anticoagulants on all-cause mortality in hospitals. We
assessed the safety of therapy related to bleeding to
provide clinical insight and consider using systemic
anticoagulants in the treatment of COVID-19 patients
in the hospital. A previous meta-analysis has asessed
the association of administration of anticoagulants in
various types (heparinoids, vitamin K antagonists, direct
anticoagulants, etc.) on all-cause mortality in hospitalized
COVID-19 patients (Flumingnan et al., 2020). However,
in our study, we focus on the systemic use of heparinoid
anticoagulants, i.e. unfractionated heparin and low
molecular weight heparin, and pentasaccharides (a
synthetic and selective anticoagulant drug similar to
low molecular weight heparin), as heparin is more
recommended for inpatients due to safety reasons related
to drug interactions (heparin does not interact with other
drugs administered to hospitalized COVID-19 patients).
We hope this systematic review and meta-analysis will
help clinicians when considering the use of heparinoid
as a systemic prophylactic anticoagulant for COVID-19
patients.
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METHODS
The systematic review and meta-analysis were
performed according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analysis (PRISMA)
Guideline (Figure 1) (Page et al., 2021).
Search Procedure
We organized a systematic review to analyze and
synthesize some of the latest studies regarding assessment
of the effect of prophylactic anticoagulants. A systematic
search was performed of the online database of Pubmed,
SpringerLink, ScienceDirect, Scopus, and ProQuest to
discover compatible articles. The primary search was
restricted to articles published during the COVID-19
pandemic from 2019 to 2021. The language was limited
to English, and we used a specific key search term
(“Anticoagulant” OR “LMWH” OR “Heparin”) AND
(“Prophylaxis” OR “Prophylactic” OR “Subtherapy”)
AND “COVID” AND “Mortality.” Employing these
data, a systematic review was conducted on the effect
of heparinoid anticoagulant at prophylactic doses on
mortality amongst COVID-19 patients. Duplicate
studies were excluded from this meta-analysis. We used
EndNote tools to help that process. Two investigators
independently explored the literature, screened titles and
abstracts, and carefully evaluated full text to analyze
potentially eligible studies. In case of disagreement, it
was consulted and solved by the consensus of all authors.
Criteria for Inclusion and Exclusion
The patients’ inclusion and exclusion criteria were
established by the Population, Intervention, Comparison,
Outcomes (PICO) formula. The population comprised
patients with confirmed COVID-19 with RT-qPCR
results and those undergoing hospitalization (any patients
COVID-19 as long they were hospitalized). Intervention
referred to heparinoid anticoagulants at prophylactic
doses (both LMWH and UFH), while the comparison was
based on patients not being given systemic prophylactic
anticoagulants or heparionoid anticoagulants at
intermediate-to-therapeutic doses. The outcomes related
to establishing the clinical outcome of using systemic
anticoagulants in the prophylactic dose and their effect
on patient mortality. On the other hand, the exclusion
criteria were: (1) non-original articles (review articles);
(2) non-clinical studies; (3) non-COVID-19 patients; (4)
patients not hospitalized; and (5) no comparison made
between heparinoid anticoagulants at prophylactic and
therapeutic doses or between prophylactic heparinoid
anticoagulant and without anticoagulant treatment.
Schemes and Search Results
5,186 articles were discovered based on an online
database search using specified keywords, including
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259 from Pubmed, 708 from SpringerLink, 1,058 from
ScienceDirect, 1,248 from Scopus, and 1,903 from
ProQuest. After screening the title, abstract and full-text
articles, 12 articles were found to match the stipulated
inclusion criteria, and the review process was resumed
(included in qualitative synthesis). The search results
schemes are summarized in Figure 1.
Data Extraction and Quality Assessment
The extracted data for characteristics comprised the
author’s name and year, inclusion/exclusion criteria,
population characteristics (age, sex), setting, followup period, and the dosage of anticoagulant treatment.
All-cause mortality was documented for the primary
outcomes, and for the treatment, safety assessment was
bleeding. We collected and provided results in the form
of narration and a table.
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The authors used the STROBE checklist to assess the
quality and authenticity of the observational researches
(von Elm et al., 2014). This checklist STROBE covers
22 quality assessment domains. Items with fully reported
detailed data received a score of 1, items with partially
reported detailed data received a score of 0.5, and items
with not reported detailed data received a score of 0. As a
result, each study had a STROBE score rate ranging from
0 to 22. Two authors reviewed each study independently
and scored them according to the STROBE checklist.
All of the disagreement was consulted and solved by the
consensus of all authors.
Data Synthesis
We planned to initiate meta-analyses only where this was
consequential, that is, if the treatments, subject, and the
underlying clinical investigation were similar enough for

Figure 1. Literature Search Scheme with PRISMA flow
E-ISSN 2477-0612

106

Pharm Sci Res, Vol 8 No 3, 2021

pooling to succeed. The comparative meta-analysis did
not include results from studies with no outcome event,
studies with poor methodological quality, or studies with
a high risk of bias. The main meta-analysis included all
studies that described adjusted estimates of the effects
of prophylaxis anticoagulant on in-hospital mortality
compared to no anticoagulant use in COVID-19 patients
who were hospitalized. We also added to the metaanalysis the effect estimate of the thromboprophylaxis
dosage compared to different dose (intermediate-totherapeutic) anticoagulants.
When feasible, we conducted meta-analysis and forest
plot using a Microsoft Excel Spreadsheet to calculate
a summary effect size (Neyeloff, Fuchs, & Moreira,
2012). By entering step-by-step formulas, statistics such
as Q and I² can be calculated using basic arithmetic
operations. Heterogeneity was determined using the I²
value, and low heterogeneity is defined as I² less than
50%, moderate heterogeneity as I² between 50% and
75%, and high heterogeneity as I² higher than 75%. A
random-effect model would be used to report the result of
heterogeneous data. If meta-analysis is not possible, for
example if there are substantial clinical, methodological,
or statistical heterogeneity across studies prevented
the pooling of data, the results will be synthesized
narratively.
RESULTS
Characteristics of the Included Studies
The review was compiled systematically to examine the
development of the latest studies (2019-2021) regarding
the impact of prophylactic systemic anticoagulants on
COVID-19 patients’ mortality through clinical reviews.
A systematic method was utilized to help readers easier
to understand the content and to avoid bias. Figure 1
shows the study selection process. In the initial literature
search using predetermined keywords, we identified a
total of 5,186 articles. After screening of the the title,
abstract and full text, 12 articles (N=8,968 patients) were
selected, which were considered suitable because they
met the inclusion criteria set. Furthermore, only 6 studies
(N=7,176 patients) continued for quantitative synthesis
by meta-analysis. The other 6 studies had heterogeneous
characteristics, different settings, and outcome units, so
meta-analysis could not be carried out.
All of the researches are retrospective observational
studies, and most are from European countries. All
the studies were based on a hospital setting, including
ICU and medical wards. Three studies focused on ICU
patients (Helms et al., 2021; Jonmarker et al., 2020;
Zheng et al., 2021). The nine other studies were based on
an all-hospitalized patient setting, apart from Pesavento
et al. (2020), who only used a medical ward patient
E-ISSN 2477-0612
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setting. In general, the study was conducted by collecting
retrospective data on treatment, outcome, the severity of
COVID-19 and comorbidities, obtained from patients’
medical records, with hospital mortality defined as any
death that occurred during hospitalization for whatever
reason. In most of studies, the primary endpoint was
“all-cause death” (Table 2).
In the 12 studies, the sample size ranged between 150
and 5000 patients; The smallest sample size was 152
patients in the study of Jonmarker et al. (2020) and the
most sample used was 4,297 patients found in the study
of Rentsch et al. (2021). All the studies involved adult
men and women (≥18 years), with the majority being
male (>55%), apart from the study of Shen et al. (2021),
in which the percentage of men was lower (49.3%) than
that of women (Shen et al., 2021) The median age for the
study was 63, with the age range varying from 54 to 73.7
years (Table 1).
Table 1 displays the overall quality assessment score
of the included studies using the STROBE guidelines
(von Elm et al., 2014). The included studies’ total scores
varied from 17 to 21, indicating that the studies’ quality
ranged from moderate to high. In general, the quality of
the studies in this systematic review is suitable based on
the scores obtained. A summary of the overall STROBE
checklist assessment is available in the Supplementary
file.
Qualitative Review: Association of Anticoagulant
Treatment with mortality
Anticoagulant prophylaxis versus non-use of
anticoagulants
In the 12 studies that were reviewed, four studies
compared prophylactic anticoagulant versus no
anticoagulant with their related with a decreased risk
of in-hospital mortality patients with COVID-19
(Albani et al., 2020; Rentsch et al., 2021; Shen et al.,
2021; Zheng et al., 2021). Of these four studies, all
used an LMWH systemic anticoagulant (enoxaparin)
at a prophylactic dose of 40 mg daily (Albani et al.,
2020; Shen et al., 2021) or 100 IU Axa/kg once per day
(Zheng et al., 2021). In contrast, Rentsch et al. (2021)
did not list the prophylactic dose of enoxaparin used
(Albani et al., 2020) (Table 2). Overall, the four studies
(N=6,375 patients) showed that prophylactic heparinoid
anticoagulant (LMWH/enoxaparin) was related with
decreased odds of mortality in patients with COVID-19:
adjusted OR 0.53, 95% CI 0.40-0.70; 1,376 participants
(Albani et al., 2020); adjusted HR 0.69, 95% CI 0.610.77; 4,297 participants (Rentsch et al., 2021); adjusted
OR 0.20, 95% CI 0.09-0.46; 525 participants (Shen et
al., 2021); unadjusted OR 0.60; 95% CI 0.32-1.01; 180
participants (Zheng et al., 2021).
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Table 1. Characteristics of the included studies

COVID-19 Patient Type

N

Age

Male sex (%)

Quality
Analysis
Score

Retrospective cohort study Sweden

ICU Patients

152

Median (IQR): 61 (52-69)

125 (82.2)

19

2020

Retrospective study

All COVID-19 inpatients

154

Median (IQR): 55 (48-66)

96 (62.34)

18

Pesavento et al.

2020

Retrospective cohort study Italy

Medical Wards Patients

324

181 (55.9)

17

Albani et al.

2020

Retrospective cohort study Italy

All COVID-19 inpatients

Median (IQR): 71
(59-82)
1376 Median (IQR) : 68 (58-76)

379 (67.15)

20

Grandone et al.

2021

Retrospective cohort study Italy

All COVID-19 inpatients

264

Median (IQR): 72 (58-80)

149 (56.4)

19

Mennuni et al.

2021

Retrospective cohort study Italy

All COVID-19 inpatients

436

Mean (SD):
71.2 (15.6)

159 (55.4)

21

Shen et al.

2021

Retrospective cohort study China

All COVID-19 inpatients

525

Median (IQR): 64 (52-72)

259 (49.3)

20

Martinelli et al.

2021

Retrospective cohort study Italy

All COVID-19 inpatients

278

Median (IQR):
59 (49-67)

181 (65.1)

20

Zheng et al.
Farrar et al.

2021
2021

ICU Patients
All COVID-19 inpatients

180
803

19
19

2021

All COVID-19 inpatients

Median (IQR): 64 (51-72)
Median (IQR):
54 (42-65)
4297 Median (IQR): 68 (58-75)

113 (62.7)
446 (55.5)

Rentsch et al.

4015 (93.4)

21

Helms et al.

2021

Retrospective study
China
Retrospective cohort study United
State
Retrospective cohort study United
States
Bicenter cohort
France

ICU Patients

179

130 (72.6)

18

Author

Year

Study Design

Jonmarker et al.

2020

Canola & Saylan

Country

Turkey

Median (IQR): 62 (51-70)

Abbreviations: ICU, Intensive Care Unit; IQR, Interquartile; SD, Standard Deviation; N, Number
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Table 2. Anticoagulant prophylaxis in COVID-19 mortality
Author/ Study
(Jonmarker
al., 2020)

Intervention

et Standard
dose
thromboprophylaxis
(for ICU patients):
2500–
5000 IU dalteparin,
or 2500–4500 IU
tinzaparin.

Comparison
Medium-dose
thromboprophylaxis:
>4500 IU tinzaparin
or <175 IU per kg
of
body
weight;
dalteparin >5000 IU
or <200 IU/kilogram
of body weight
Thromboprophylactic
therapy at the high
dose (for patients
with thromboembolic
disease) ≥175 IU
per kg tinzaparin or
≥200
IU/kilogram
dalteparin

Follow up
treatment follow
up
Patients
were
monitored
until they died
or until the 28th
day after being
admitted to the
ICU

Outcome
assessment

Mortality
A vs. B (%)

OR/HR

The primary
outcome was
mortality
at
28-day

Patients
who
received
high: lower : medium-dose
prophylactic = 13.5% : 25.0%
: 38.8%

In comparison to low-dose
thrombophylaxis, the HR of death for
high dose was 0.33 (95% CI 0.13–
0.87) and 0.88 (95%.CI 0.43–1.83) for
medium dose.

(Canoglu
& prophylactic LMWH : therapeutic
Patients
were I n - h o s p i t a l
Saylan, 2020)
0.5 mg/kg twice daily Dose: 1 mg/kg twice tracked from the mortality
daily
time they were
admitted to the
hospital until the
earliest data on
outcomes
were
available.
(Pesavento
al., 2020)

et Prophylactic
doses:
UFH 5000 UI TID, 40
mg OD of LMWH, 2.5
mg daily Fondaparinux

E-ISSN 2477-0612

Subtherapeutic doses:
1 mg/kg BID of or
0.5 mg/kg BID of
LMWH, 7.5 mg of
Fondaparinux

44.9% (98 patients) with Prophylactic dose LMWH had a higher
prophylactic
risk of mortality than the therapeutic
dose of LMWH died
dose (OR 6.495; 95% CI 2.393-17.627)
17.9% (10 patients) of 56
patients with therapeutic
Dose of LMWH died

Patients
were O v e r a l l Overall mortality rates were
tracked from the mortality
12.2 per 100 people per month
time they were
in the prophylactic group and
admitted to the
20.1 per 100 in the (sub)
hospital until the
therapeutic group.
earliest data on
outcomes
were
available.

Overall
mortality
rates
were
12.2/100-person/months (95% CI 8.117.8) in the prophylactic dose group
and 20.1/100 person/month (95% CI
11-33.6)
Anticoagulant sub-therapeutic dosages
are associated with an increased risk
of all-cause death (HR 3.89;95% 1.907.90)
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Table 2. continued
Author/ Study

Intervention

Comparison

(Albani et al., Enoxaparin: 40-80 mg without enoxaparin
2020)
in daily

(Grandone
al., 2021)

et Prophylactic LMWH: Intermediate
and
40 mg once a day
therapeutic dose of
LMWH: 40 mg every
12 hours or 60 mg
once a day
Therapeutic dose: 100
U/Kg every 12 hours

Follow up
treatment follow
up
Patients
were
tracked
until
they died or were
discharged from
the hospital.

Outcome
assessment

Patients
tracked
they died or
discharged
the hospital.

P r i m a r y
outcome:
all-cause
mortality

were
until
were
from

(Mennuni et al., P r o p h y l a c t i c Enoxaparin at higher The
outcome
2021)
enoxaparin dosage: 40 dose: >40 mg per day of all events
mg per day
(both
primary
and secondary)
was
assessed
from
events
that occurred at
admission
and
after the patient
received LMWH
treatment.

Mortality
A vs. B (%)

the primary No Enoxaparin: 154 (25.5
o u t c o m e %)
was hospital Enoxaparin: 200 (25%)
mortality

OR/HR
Compared to no enoxaparin treatment,
enoxaparin was related to decreased inhospital all-cause mortality (OR 0.53,
95% CI 0.40-0.70, with an E-value of
2.08 (upper CI 1.66).

prophylaxis with
LMWH usage in prophylactic dosage
LMWH reduces by almost has lowered mortality considerably (OR
70% mortality in patients 0.31, 95% CI 0.13-0.85)
with
mild/moderate disease

P r i m a r y All-cause death Prophylactic
o u t c o m e : dose (A) 25.4% vs Higher
a l l - c a u s e dose (B) 26.9%
mortality

Prophylactic dose LMWH is related to
decreased risk of all-cause mortality:
Adjusted OR 0.847 (95% CI 0.4001.792)
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Table 2. continued

Author/ Study
(Shen
2021)

et

(Martinelli
al., 2021)

Intervention

Comparison

al., Prophylactic LMWH: Without LMWH
40 mg subcutan once
a day or 40 mg every
12 hours

et The standard dose
of
prophylactic
enoxaparin: 40 mg
once a day, increased
to 60 mg a day in
obese patients

High
dose
of
prophylactic
enoxaparin :
0.7-1 mg/kg twice
daily

Follow up
treatment follow
up
Patients
were
tracked
until
they died or were
discharged from
the hospital.

Mortality
A vs. B (%)

Primary outcome: In-hospital mortality in
in-hospital
all- mild/moderate
patients
cause mortality
was 0% (LMWH) vs 1.7%
(Non LMWH), in severe
patient 2.4% (LMWH) vs
18.8% (non LMWH), and in
critically ill patient 37.31%
(LMWH) vs 63.63% (non
LMWH)

Patients
were Primary outcome:
f o l l o w e d in-hospital
alluntil
endpoint cause mortality
(cumulative
incidence at 21
days) or
discharge
from
hospital or change
in antithrombotic
therapy

(Zheng et al., Thromboprophylactic N
o Estimation of ICU
2021)
e n o x a p a r i n : thromboprophylaxis
survival rate: 30enoxaparin was given
day survival after
once a day at a dose of
admission to the
100 IU Axa/ kg for at
ICU
least 5 days
For
COVID-19
inpatients with VTE
suspects:100 IU Axa/
kg twice a day

E-ISSN 2477-0612

Outcome
assessment

Primary outcome:
survival
rate/
mortality in ICU
patient

Cumulative incidence of
death/in-hospital mortality
in standard dose 23.6%) vs.
40.2 % in the higher dose.

OR/HR
LMWH was linked to decreased allcause death (Adjusted OR 0.2; 95%
CI, 0.09-0.46) than non-LMWH.
In subgroup analysis, LMWH was
related with lower death in severe
(adjusted OR 0.08, 95% CI 0.010.06) and critical patients (Adjusted
OR 0.32; 95% CI 0.10-0.996)
Patients
receiving
standarddose enoxaparin had a decreased
cumulative incidence of mortality at
21 days than the higher dose (adjusted
HR 0.39; 95 percent CI 0.18-0.76)

Non-survivor
in The thromboprophylaxis group had a
thromboprophylaxis group lower 30-day mortality rate than the
21.67% vs 27.78% (non- no-thromboprophylaxis group (OR
thromboprophylaxis)
0.60; 95% CI 0.32-1.01)
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Table 2. continued

Author/ Study

Intervention

Follow up
treatment follow
up
Off-protocol
(other Patients
were
than
prophylactic tracked
until
regiment)
they died or were
discharged from
the hospital.
Comparison

(Farrar et al., Per-protocol (received
2021)
thromboprophylaxis):
Standard prophylactic
doses
could
be
recommended
initially, the dose
could be escalated
based on patientspecific characteristics
(admitted
to
the
Hospital consensus).
Specific dose not
mentioned in studies
(Rentsch et al., Prophylactic
No anticoagulant
2021)
anticoagulant

Patients
were
tracked from the
time they were
admitted to the
hospital until the
earliest data on
outcomes
were
available.

Outcome
assessment

Mortality
A vs. B (%)

Secondary
outcome:
all-cause
m o r t a l i t y,
major bleeding

All-cause mortality in per- Mortality in off-protocol had a higher
protocol was significantly death risk than on-protocol (OR: 2.5;
lower (6.3%) than off- 95% CI 1.36-4.56)
protocol (11.8%)

The primary
outcome was
mortality
at
30-days

The cumulative incidence
of mortality at 30 days
for individuals receiving
prophylactic anticoagulant:
agents those getting no
anticoagulant was 14.3
percent vs.18.7 percent

OR/HR

Prophylactic
anticoagulant
was
associated with a lower risk of inpatient
mortality compared to no anticoagulant
use (aHR 0.69; 95% CI 0,61-0,77)
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Table 2. continued

Author/ Study

Intervention

(Helms et al., A prophylactic dose
2021)
of enoxaparin: 60 mg
twice daily in obese
patients or UFH 200
IU/kg once a day
in individuals with
creatinine
clearance (ClCr) less
than 30 mL/min.

Comparison
Therapeutic dose: 100
IU/kg twice day of
LMWH based on body
weight, not to exceed
10,000 IU/12 h or 500
IU/kg daily of UFH
for individuals with
creatinine clearance
(ClCr) less than 30
mL/min

Follow up
treatment follow
up

Outcome
assessment

Follow-up
for Mortality
the most recently ICU
admitted patients
lasted 80 days.

Mortality
A vs. B (%)
in Prophylactic: 20 (18.5 %)
Therapeutic: 11 (15.5%)

OR/HR
Therapeutic dose treatment was
associated with decreased ICU mortality
than prophylactic dose treatment (OR
0.84; 95%CI 0.43-1.13)

Abbreviations: LMWH, Low Molecular Weight Heparin; UFH, Unfractionated Heparin; ICU, Intensive Care Unit; BMI, Body Mass Index; IU, International Unit; VTE, Venous Thromboembolism Event; IPTW, Inverse
Probability of Treatment Weighted OD, Once Daily; BID, Bis In Die (Twice in Daily); TID, Ter In Die (Three times in daily); RBC, Red Blood Cell OR, Odds Ratio; HR, Hazard Ratio; CI, Confidence Interval; NR: Not
Reported
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Shen et al. (2021) conclude that the use of prophylactic
LMWH is related to decreased all-cause mortality
when compared to no LMWH use (adjusted OR 0.2,
95% CI 0.09-0.46; 525 participants) after adjusting for
some covariates age, sex, severity classification and
comorbidities (Shen et al., 2021). These results align with
Albani et al. (2020) study of 1376 hospitalized patients,
which reported that mortality in enoxaparin intervention
was 25% and in the comparator group was 25.5%.
Enoxaparin is related to a decreased in-hospital mortality
rate correlated to no enoxaparin usage (OR 0.53, 95%
CI 0.40-0.70) (Albani et al., 2020). Furthermore, the
study conducted by Rentsch et al. (2021), with a larger
sample size (4.297 patients), reported an association
between the use of prophylactic anticoagulants and
reduced death rates within 30 days when compared to
no use of prophylactic anticoagulants after multivariate
adjustment (aHR 0,69; 95% CI 0,61-0,77) (Rentsch et
al., 2021). In addition, Zheng et al. (2021) compared
the thromboprophylaxis effect of enoxaparin versus no
thromboprophylaxis using an ICU patient setting and
assessing 30-day survival after ICU admission. The
group of patients who received thromboprophylaxis
had a lower 30-day mortality rate than the group who
did not get thromboprophylaxis (21.67% vs. 27.78%),
thromboprophylaxis group had a lower mortality rate
than the non-thromboprophylaxis group (unadjusted OR
0.60, 95% CI 0.32-1.01;180 participants) (Zheng et al.,
2021).
Anticoagulant prophylaxis dose versus anticoagulant
therapeutic dose
Eight studies compared the use of different doses of
anticoagulants. (Canoglu & Saylan, 2020; Farrar et
al., 2021; Grandone et al., 2021; Helms et al., 2021;
Jonmarker et al., 2020; Martinelli et al., 2021; Mennuni
et al., 2021; Pesavento et al., 2020). The definition of
the anticoagulant dose, either standard prophylactic,
intermediate or therapeutic, was varied in each study
(Table 2). Most studies used prophylactic anticoagulant
systemic therapy LMWH/enoxaparin. Some of
the standard prophylactic doses reported included
enoxaparin 40 mg once daily or 0.5 mg per kg twice a
day, UFH 5000 IU, 2.5 mg of fondaparinux, 2500-5000
IU dalteparin, and 2500-4500 Itinzaparin (Table 2)
(Albani et al., 2020; Canoglu & Saylan, 2020; Jonmarker
et al., 2020; Pesavento et al., 2020; Shen et al., 2021).
Pesavento et al. (2020) reported the study in 324
hospitalized patients that “all-cause mortality” at
standard dose prophylaxis (12.2 per 100 person/month;
95%CI 8.1-17.8) was lower than subtherapeutic doses
(20.1 per 100 persons/month; 95% CI 11.0–33.8)
(Pesavento et al., 2020). These results are supported by
research from Grandone et al. (2021) in 264 hospitalized
patients; they reported that prophylactic LMWH
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administration significantly reduced mortality when
compared to higher doses (OR 0.31, 95% CI 0.130.85) (Grandone et al., 2021). Furthermore, Mennuni et
al. (2021) reported that prophylactic doses of LMWH
were associated with lower in-mortality risk when
compared to greater dosages (Adjusted OR 0.847;
95% CI 0.400-1.792; 436 participants) (Mennuni et
al., 2021). Martineli et al. (2021) also reported results
that the standard prophylactic enoxaparin had a lower
percentage of mortality incidence than the higher dose
group (adjusted HR 0.39; 95%CI 0.18-0.76) (Martinelli
et al., 2021). However, these results are in contrast to
those of Canoglu & Saylan. (2020), who reported that
prophylactic doses of LMWH had a higher risk of death
than therapeutic doses (OR 6,495; 95 percent CI 2,39317,627; 154 participants) (Canoglu & Saylan, 2020).
Jonmarker et al. (2020) and Helms et al. (2021)
discovered that anticoagulant use was related to a
survival advantage in ICU patients (Helms et al., 2021;
Jonmarker et al., 2020). In Jonmarker et al. (2020) study
reported that lower risk of ICU mortality was associated
with higher dose thromboprophylaxis, both in highdose thromboprophylaxis (HR 0.33; 95%CI 0.13–0.87)
and medium-dose thromboprophylaxis (HR 0.88; 95%
CI 0.43–1.83) compared to patients who received lowdose thromboprophylaxis (Jonmarker et al., 2020).
These results are in line with Helms et al. (2021); their
study of 179 ICU patients also reported that prophylactic
anticoagulant administered to them resulted in higher
mortality compared to therapeutic doses (18.5%
vs.15.5%) (Helms et al., 2021).
In another study, Farrar et al. (2021) compared an onprotocol group (receiving prophylactic anticoagulant
according to the protocol) and an off-protocol group,
reporting a higher incidence of death in the latter than
the former (OR: 2.5; 95 percent CI 1.36-4.56 ) in patients
with D-dimer 1500ng/ml (Farrar et al., 2021).
Qualitative Review: The Anticoagulant Safety Profile
in COVID-19 Patients
Safety assessment of the use of anticoagulants must also
be considered when treating COVID-19 patients. Major
bleeding events are one of the most frequent adverse
effects of using systemic anticoagulants. Studies have
reported various types of bleeding events (both major
and non-major) in COVID-19 hospitalized patients
receiving anticoagulant Treatment (Albani et al., 2020;
Farrar et al., 2021; Grandone et al., 2021; Helms et al.,
2021; Jonmarker et al., 2020; Martinelli et al., 2021;
Mennuni et al., 2021; Pesavento et al., 2020; Rentsch
et al., 2021; Shen et al., 2021),, apart from two studies
that did not assess such events (Canoglu & Saylan, 2020;
Zheng et al., 2021).
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Figure 2. The Pooled Effect Size of mortality among COVID-19 patients in hospitalization with anticoagulant:
(A) prophylaxis anticoagulant compared to patients without anticoagulant use, (B) Prophylaxis dose compared
to intermediate-to-therapeutic dose anticoagulant, abbreviation: df, degree of freedom
Most studies report a higher incidence of bleeding
with higher prophylactic doses of anticoagulants
(intermediate/sub-therapeutic)
than
standard-dose
prophylaxis (Grandone et al., 2021; Jonmarker et al.,
2020; Martinelli et al., 2021; Mennuni et al., 2021;
Pesavento et al., 2020). Pesavento et al. (2020) reported
that the incidence of significant bleeding in the (sub)
therapeutic dose group was higher (9.5%) than the
standard prophylactic dose group (3.3%) (Pesavento
et al., 2020). Jonmarker et al. (2020) also show similar
results; the proportion of bleeding events in low dose
prophylactic was lower (11.9%) than the higher dose
prophylactic (14.6%), respectively (p=0.16) (Jonmarker
et al., 2020). These results align with Mennuni et al.
(2021); they reported a relatively low incidence of
bleeding events in both groups. Major bleeding in the
prophylaxis dose regimen was lower than the higher
dose regimen, although the difference was insignificant
(Mennuni et al., 2021). Furthermore, the research by
Martinelli et al. (2021) also reported that major bleeding
happened in 4/127 patients (3.1%) in higher dose
enoxaparin, while no bleeding events were observed in
the standard dose prophylactic group (Martinelli et al.,
2021).
E-ISSN 2477-0612

Several other studies reported bleeding events in the
group receiving anticoagulants compared to those
without anticoagulants (Albani et al., 2020; Farrar
et al., 2021; Rentsch et al., 2021; Shen et al., 2021).
Rentsch et al. (2021) report no risk of severe bleeding
events; according to the results of a post hoc safety test,
prophylaxis anticoagulant was not related to a higher
incidence of bleeding with a need for transfusion when
compared to non-anticoagulant use and bleeding events
that required transfusion was rare (4.6%) (Rentsch et
al., 2021). The study of Shen et al. (2021) also reported
no statistical difference in the major bleeding event
between individuals receiving LMWH anticoagulants (2
patients) and those who did not (1 patient) (Shen et al.,
2021). Furthermore, the research conducted by Farrar et
al. (2021) reported that the on-protocol group (receiving
prophylactic therapy according to the protocol) had a
considerably lower bleeding percentage than the offprotocol group (3.1% vs. 9.6%, p <0.001) (Farrar et al.,
2021). Moreover, Albani et al. (2020) reported results,
with its prophylactic enoxaparin group having a lower
percentage of bleeding events than without enoxaparin
(1.2% vs. 2.5%). However, the difference was not
significant (Albani et al., 2020).
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Quantitative: Meta-Analysis
Of the 12 research cited above, 3 were conducted in the
ICU setting, while the other 9 were in the all-hospitalized
setting (Helms et al., 2021; Jonmarker et al., 2020).
Four of the 9 studies compared the use of prophylactic
anticoagulants with non-anticoagulant usage (Albani et
al., 2020; Farrar et al., 2021; Rentsch et al., 2021; Shen
et al., 2021). The other 5 studies compared the use of
standard prophylactic dose anticoagulants to higher dose
(intermediate-to-therapeutic) anticoagulants (Canoglu &
Saylan, 2020; Grandone et al., 2021; Martinelli et al.,
2021; Mennuni et al., 2021; Pesavento et al., 2020).
Six observational studies with 7.176 hospitalized
COVID-19 patients were involved in the quantitative
meta-analysis with some considerations (Albani et al.,
2020; Grandone et al., 2021; Martinelli et al., 2021;
Mennuni et al., 2021; Rentsch et al., 2021; Shen et
al., 2021). We performed to compare prophylactic
anticoagulant to without anticoagulant used. Moreover,
we independently considered the association of
heparinoid anticoagulant at prophylactic doses with
in-hospital mortality compared to intermediate-totherapeutic dose anticoagulant. Based on the pooling
effect size results, the prophylactic dose of anticoagulant
significantly reduces the risk of mortality by 40-50%.
Administration of prophylactic doses of anticoagulants
decreased mortality compared with no anticoagulants
and intermediate-to-therapeutic anticoagulants.
In comparison between prophylactic anticoagulant
versus no anticoagulant use, we performed a combined
meta-analysis of 3 studies. Farrar et al. (2021) should
be excluded because of methodological differences, and
the adjusted association of anticoagulants to the use of
anticoagulants in-hospital mortality was not reported. By
pooling the result of the three studies on all COVID-19
patients, the risk of in-hospital mortality was reduced
by 53% (pooled OR 0.47; 95% CI 0.19-0.76; I²= 0%)
(Figure 2A). In addition, compared with intermediateto-therapeutic dose anticoagulants, prophylactic dose
anticoagulants were also associated with decreased
risk of in-hospital mortality in COVID-19 patients
hospitalized (pooled OR 0.51; 95% CI 0.21-0.82,
I²=12.4%, three studies, N= 978) (Figure 2B). Canoglu
& Saylan (2020) and Pesavento et al. (2020) were
excluded from the meta-analysis because they reported
different methodological and the adjusted effect size.
In our study, we could not perform a pooling metaanalysis of 3 studies in the ICU setting. This is due to
the absence of reported adjusted associations between
anticoagulant use and in-hospital all-cause mortality in
the study of Helms et al. and Zheng et al., which prevented
the pooling of data, so data were synthesized narratively.
The pooling meta-analysis could not be reported in
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assessing bleeding events because most studies did not
report adjusted association anticoagulant use in bleeding
events. They only reported the proportion of bleeding
events in each study that prevented the pooling of
data, and the data were synthesized narratively (in the
Qualitative review section).
DISCUSSION
The present study’s main finding is that using heparinoid
as a prophylactic systemic anticoagulant was related
to a substantially reduced risk of in-hospital mortality
in COVID-19 patients who were hospitalized. For
hospitalized COVID-19 patients, heparin was suggested
in some treatment guidelines. Not only employed as an
anticoagulant, but heparin can also be used as an antiviral
and anti-inflammatory treatment. It can bind to the spike
protein in SARS-CoV-2 and act as a viral inhibitor
to break down infectiousness (Buijsers et al.,2020).
Previous in vitro studies reported that the SARS-CoV-2
spike protein interacts with a greater affinity for heparan
sulfate than the SARS-CoV or MERS-CoV spike protein
(Kim et al., 2020). Tree et al. (2021) also reported that
UFH had a solid antiviral effect, with IC50 values ranging
25-41 μg/ml, while LMWH had a lower inhibitory ability
(IC50 values range 3.4-7.8 mg/ml) (Tree et al., 2021).
Heparin’s ability to inhibit SARS-CoV-2 infection was
reported to depend on the concentration used. Heparin
was shown to effectively inhibit 70% of SARS-CoV-2
in Vero cells at a concentration of 100 mg/ml (MycroftWest et al., 2020). As an anti-inflammatory, heparin is
reported to reduce NF-B signaling to the endothelium,
resulting in decreased synthesis of pro-inflammatory
cytokines such as TNF, IL6, and IL-1. This mechanism
can be used to prevent the occurrence of cytokine storms,
which can worsen the prognosis of COVID-19 patients
(Hippensteel et al., 2020).
Heparin’s potential as a commonly used anticoagulant
has proven to be very strong (Albani et al., 2020; Farrar
et al., 2021; Grandone et al., 2021; Mennuni et al.,
2021; Rentsch et al., 2021; Shen et al., 2021). However,
its optimal dose and the possibility of bleeding are of
particular concern in its use. Research on the optimal dose
of anticoagulants is still at the development stage. The
risk of bleeding especially concerns the administration
of anticoagulant therapy, and the occurrence of inpatient
mortality is also associated with that of major bleeding
after such therapy (Khan et al., 2020).
Most of the studies obtained results showing that
prophylactic doses of anticoagulants reduced mortality
(Grandone et al., 2021; Mennuni et al., 2021; Shen et
al., 2021; Martinelli et al., 2021; Albani et al., 2020;
Martinelli et al., 2021; Pesavento et al., 2020). Most of
them are studied from Italy and Iran (study Pesavento et
E-ISSN 2477-0612
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al.). However, two studies from the other country (study
Canouglu et al. from Turkey and study Helms et al. from
France) produced different results regarding the effect
of prophylactic and therapeutic doses on mortality rates
(Canoglu & Saylan, 2020; Helms et al., 2021). Canoglu
& Saylan (2020) and Helms et al. (2021) reported that
prophylactic doses of LMWH posed a higher risk
than therapeutic doses of LMWH. Canoglu & Saylan
(2020) established 0.5 mg per kg every 12 hours as a
prophylactic dose and 1 mg per kg every 12 hours as a
therapeutic dose. On the other hand, Helms et al. (2021)
used prophylactic doses of UFH 6000 IU twice a day
subcutaneously in patients with obesity or UFH 200 IU
per kg daily in creatinine clearance (ClCr) less than 30
mL/min. Meanwhile, the therapeutic dose of LMWH is
100 IU per kg every 12 hours subcutaneously according
to body weight, with a maximum dose of 10,000 IU twice
every 12 hours or UFH 500 IU per kilogram daily for
individuals with creatinine clearance less than 30 mL/
min (Helms et al., 2021). However, most studies report
that prophylactic doses have a lower risk of mortality
than therapeutic ones.
The standard prophylactic doses reported include
enoxaparin 40 mg once daily (Grandone et al., 2021;
Mennuni et al., 2021; Shen et al., 2021; Martinelli et al.,
2021), enoxaparin 40 mg-80 once daily (Albani et al.,
2020), enoxaparin 60 mg twice daily in obese patients
(Martinelli et al., 2021); and 2.5 mg fondaparinux
(Pesavento et al., 2020) (see Table 2). Apart from
the definition of different doses, the differences in
results may be influenced by other factors, including
the essential characteristics of patients, their clinical
condition, and standard of care in each country which
are pretty diverse. While studies reviewed are ongoing,
the standard of care for thromboprophylaxis use for
COVID-19 patients was still very diverse. Although in
April 2020, the International Society on Thrombosis
and Haemostasis (ISTH) published recommendations
for thromboprophylaxis with enoxaparin for COVID-19
patients, they specified the prophylactic dosage of
LMWH as enoxaparin 4,000UI or 40 mg subcutaneously
every 12 hours. The evidence for this recommendation
is inadequate, and evidence of a mortality advantage
in individuals treated with enoxaparin is insufficient,
primarily since COVID-19 is a novel disease (Thachil
et al., 2020). The results of the studies reviewed can
illustrate that standard prophylactic doses are shown
to reduce patient mortality further. The standard dose
commonly used in the studies reviewed is LMWH
(enoxaparin) 40 mg once daily.
The studies’ results proved that treatment with a
systemic prophylactic anticoagulant during hospital
stay reduce themortality. Moreover, when prophylactic
anticoagulants are taken on the general ward, the
E-ISSN 2477-0612
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probability of ICU admission is reduced (Albani
et al., 2020). Nevertheless, ICU patients need a
high-dose anticoagulant because adjusted dosing is
influenced by characteristic patients, including the risk
of thromboembolic complications (Mennuni et al.,
2021). There is a consensus reporting an increased risk
of thromboembolic events in 20-43% of COVID-19
patients admitted to ICUs despite receiving prophylactic
anticoagulants. The most common occurrences are
pulmonary embolism and vein thrombosis of the
lower extremities (Pluta, Cieniewicz, & Trzebicki,
2021). A high rate of thrombotic complications has
been reported in patients with COVID-19 in the ICU.
In a systematic screening report, many events of
thrombotic complications would be missed by relying
solely on clinical suspicion, so increasing the dose of
thromboprophylactic anticoagulants in the ICU should
be considered (Jenner et al., 2021).
In our meta-analysis, compared to the non-anticoagulant
group, using a prophylactic dosage anticoagulant
reduced the risk of in-hospital mortality by 53%; this
might imply that using a prophylactic dose anticoagulant
as a part of COVID-19 treatments may be advantageous.
In addition, standard-dose prophylactic heparinoid
anticoagulant was associated with decreased in-hospital
mortality more than intermediate-to-therapeutic dose
anticoagulant (pooled OR 0.51; 95% CI 0.21–0.82,
I2= 12.4%, three studies, N=978 ). In contrast to the
results of Kamel et al. (2021), they discovered that the
prophylactic anticoagulant dosage might be related to
increased in-hospital mortality compared to therapeutic
anticoagulant dose (RR 1.58, 95 % CI 1.34-1.87, three
studies, N=963) (Kamel et al., 2021). These conflicting
results are because of the wide variety of the study
setting, populations, the patient clinical condition, type
of healthcare, and therapeutic approaches. In addition,
when studies reviewed are ongoing, the primary
guidance has not yet established a standardized regimen
for managing patients with COVID-19, so the standard of
care for thromboprophylaxis use for COVID-19 patients
in each study was still very diverse. To ascertain a more
apparent optimal dose, it is necessary to standardize the
definitions of standard, intermediate, and therapeutic
doses and monitor patients’ clinical conditions. The
studies included had varying degrees of COVID-19
severity and suggested that heparinoid (especially
LMWH) may benefit patients in the mild/moderate and
severe ill COVID-19. These results are per the ISTH
interim guidance, which recommends using LMWH in
COVID-19 patients who have been hospitalized (Thachil
et al., 2020). The American Society of Hematology
(ASH) recently proposed using the prophylaxis
anticoagulants doses rather than the intermediate and
therapeutic anticoagulant doses in COVID-19 patients.
However, this suggestion was based on evidence with a
low degree of certainty (Cuker et al., 2021).
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In addition to the dose, the adverse effects of
anticoagulants were also investigated, as bleeding
needs to be considered in the administration of systemic
anticoagulants. Bleeding remains a major safety concern
when anticoagulant is administered in COVID-19
patients with coagulation disorders. Bleeding events, as
measured by our study was relatively rare in anticoagulant
therapy. Our result reported no statistically significant
difference in major bleeding events between individuals
receiving prophylactic anticoagulants and those who did
not. Billet et al. (2020) reported that a higher probability
of transfusion was not associated with any anticoagulant
regimen (both prophylactic and therapeutic dose
anticoagulant) (Billett et al., 2020). Jonmarker et al.
(2020) stated no signs of higher bleeding in the critically
ill patients with COVID-19 who received higher doses
of anticoagulants; this could be due to the characteristics
of patients who may not bleed easily even with larger
doses (Jonmarker et al., 2020). According to our study,
the incidence of the bleeding event was relatively low in
both standard prophylactic dose group and intermediateto-therapeutic dosage, despite the proportion of bleeding
event in standard prophylactic dose was lower than the
higher dose. However, this risk does not lead to death,
indicating that it can be safely used in this clinical
setting. The studies reviewed to establish that there is
potential for standard prophylactic anticoagulants to
reduce mortality rates. However, their use needs to be
made with intensive monitoring of therapy and side
effects.
LIMITATIONS
This systematic review’s strength is that it provides
systematic information on the effects of heparinoids as
systemic anticoagulants prophylactic on all-cause-death
from COVID-19 in hospitals. It also evaluates the safety
of therapy related to bleeding that has not previously been
made. However, the study has limitations because the
population engaged is limited (confined to a few regions
and does not cover all countries and continents). All of
the identified studies in our analysis were observational
and retrospective; as a result, the association’s strength
could not be adequately determined. There are variances
across studies that will lead to bias, such as differences in
the setting (ICU and general wards), variations in the type
of health facilities where the study took place; varying
standards of care or protocol therapy in each country;
and differences in dose and type of thromboprophylactic
anticoagulant. Moreover, some studies did not report
the exact prophylactic dose used. Furthermore, item
scoring in quality assessment is still a subjective process
that might lead to subjective bias. However, we have
minimized subjective bias by independently assessing the
study using the STROBE statement by two investigators,
and the differences were resolved by discussion. The
last, although the results of this meta-analysis were
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significant, extrapolation of these data studies should
be done with caution because no randomized controlled
trials were conducted on the systemic anticoagulants or
LMWH included in this meta-analysis. Further research,
including RCTs on the effects of systemic or heparinoid
anticoagulants in patients with COVID-19, might help to
explain and confirm the findings.
CONCLUSION
We discovered that using heparinoid as systematic
prophylactic anticoagulant was associated with
decreased in-hospital mortality in COVID-19 patients
without an increase in bleeding events, despite the
severity of their disease. The reduction in mortality
associated with prophylactic heparinoid anticoagulant
may be related to the prevention of the coagulopathy that
commonly occurs in the development of COVID-19.
Administration of prophylactic anticoagulants at higher
doses (intermediate-to-therapeutic dose anticoagulant)
benefits increasing survival rates, especially for ICU
patients. However, the risk of bleeding is higher than with
standard doses. Therefore, standard-dose prophylactic
heparinoid anticoagulant (40 mg once daily of LMWH)
should be considered for patients with non-critical or
other conditions without contraindications. RCT clinical
trials are required to establish conclusions about the
potential effectiveness of this therapy in COVID-19
patients.
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